Subscribe to Press Releases


Immunotherapies for Life

YmAbs Announces Phase I Omburtamab Data

Omburtamab as intraperitoneal radioimmunotherapy in desmoplastic small round cell tumor
Read more


YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management are added to Y-mAbs’ list of institutional shareholders
Read more


YmAbs Raises $50 Million in Equity Financing

Y-mAbs Therapeutics, Inc. closes $50 million in a private placement led by HBM Healthcare Investments (HBM) and supported by current shareholders
Read more


YmAbs Granted Rare Pediatric Disease Designation for hu3F8 Antibody

The FDA grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for hu3F8 for the treatment of Neuroblastoma
Read more